Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
Management
Luca Benatti, the Company’s Managing Director and Chief Executive Officer since 1998, founded Newron in 1998 along with Dr. Ruggero Fariello and Dr. Patricia Salvati.
Patricia Salvati has been the Company’s Vice President, Discovery since she co-founded Newron in 1998 along with Dr. Benatti and Dr. Fariello.
Stefano Rossetti has been the Company’s Vice President of Development since May 2003.
Marco Caremi has been the Company’s Vice President of Strategic Marketing and Head of Legal Affairs since February 2007.
Stefan Weber has been the Company’s Chief Financial Officer since April 2005.
Ravi Anand has been the Company’s Chief Medical Officer since May 2005.
Carlos de Sousa is a senior pharmaceutical executive with 19 years experience in the industry.